Skip to main content
. Author manuscript; available in PMC: 2010 Mar 27.
Published in final edited form as: AIDS. 2009 Mar 27;23(6):661–672. doi: 10.1097/QAD.0b013e3283269dfb

Table 4.

Predicted Change in Laboratory Outcomes Per Year of Current ARV Use

OUTCOMES PI NRTI NNRTI
Lipids
Cholesterol
 Total Ritonavir 3
2.5 (1.3, 3.6 )
p<0.001 4 		Nelfinavir
1.5 (0.4, 2.6 )
p=0.008		 Other PI 2
0.5 (-1.5, 2.5 )
p=0.651		 NRTI
-0.3 (-1.3, 0.6)
p=0.480		 NNRTI
0.1 (-1.0, 1.2 )
p=0.829
 LDL Ritonavir 3
2.4 (0.8, 4.2)
p=0.004		 Nelfinavir
2.5 (0.9, 4.1 )
p= 0.002		 Other PI 2
-0.2 (-3.0, 2.7 )
p=0.895		 NRTI
-0.3 (-1.6, 1.0 )
p=0.652		 NNRTI
-0.9 (-2.4, 0.7 )
p=0.288
 HDL Nelfinavir
-1.4 (-2.7,-0.0 )
p= 0.046		 PI
-1.0 (-2.4, 0.4 )
p=0.159		 ZDV
-1.2 (-2.1, -0.2 )
p=0.016		 Other NRTI 1
0.4 (-0.9, 1.7 )
p=0.525		 Nevirapine
1.7 (0.1, 3.3)
p=0.043		 Efavirenz
1.9 (-0.1, 3.9)
p=0.060
 Non-HDL Ritonavir 3
3.7 (2.1, 5.3 )
p<0.001		 Nelfinavir
2.3 (0.8, 3.9 )
p=0.003		 Other PI 2
1.8 (-0.8, 4.4 )
p=0.184		 NRTI
-0.3 (-1.5, 1.0 )
p=0.636		 NNRTI
0.2 ( -1.3, 1.7)
p=0.830
 Triglycerides Ritonavir 3
7.7 (4.7, 10.7 )
p<0.001		 Nelfinavir
3.3 (0.5, 6.1 )
p=0.021		 Other PI 2
2.9 (-1.9, 8.0)
p=0.242		 ddI
-2.8 (-4.9, -0.7 )
p=0.009		 Other NRTI 1
-1.2 (-3.4, 0.9)
p=0.264		 NNRTI
0.0 ( -2.7, 2.8)
p=0.989
Glucose
Metabolism
 Fasting glucose Nelfinavir
-0.4 (-0.8, -0.1 )
p=0.014		 Other PI 2
-0.2 (-0.6, 0.1 )
p=0.243		 NRTI
-0.1 (-0.4, 0.1 )
p=0.334		 NNRTI
0.3 (-0.0, 0.7 )
p=0.065
 2-hour glucose Ritonavir 3
1.2 (0.2, 2.2 )
p=0.018		 Other PI 2
0.5 (-0.4, 1.5 )
p=0.281		 NRTI
-0.3 (-1.2, 0.6 )
p=0.476		 NNRTI
0.1 (-0.9, 1.1 )
p=0.866
 Fasting insulin PI
-0.3 (-3.2, 2.8 )
p=0.852		 NRTI
0.1 (-2.6, 3.0 )
p=0.922		 NNRTI
1.6 (-1.8, 5.1 )
p=0.355
 2-hour insulin Ritonavir 3
8.0 (3.3, 12.8 )
p<0.001		 PI
2.4 (-1.8, 6.7 )
p=0.270		 Other NRTI
2.8 (-1.0, 6.8 )
p=0.154		 NNRTI
-0.3 (-4.7, 4.3 )
p=0.901
 HOMA-IR PI
-0.3 (-3.3, 2.9 )
p=0.859		 NRTI
-0.5 ( -3.4, 2.4)
p=0.718		 NNRTI
2.1 (-1.4, 5.7 )
p=0.251
 Fasting C-peptide PI
-0.5 (-2.4, 1.5 )
p=0.641		 ddI
-1.8 (-3.4, -0.1 )
p=0.044		 Other NRTI 1
0.1 (-1.7, 1.8 )
p=0.940		 NNRTI
0.7 (-1.5, 2.8 )
p=0.540
 2-hour C-peptide Ritonavir 3
4.2 (1.5, 6.9 )
p=0.002		 Other PI 2
0.1 (-2.4, 2.6 )
p=0.951		 NRTI
1.4 (-0.8, 3.7 )
p=0.208		 NNRTI
-1.1 (-3.7, 1.6 )
p=0.437
Lactate PI
0.9 (-0.7, 2.5 )
p=0.276		 NRTI
-1.0 (-2.4, 0.5 )
p=0.194		 NNRTI
-0.5 ( -2.2, 1.3)
p=0.582
1

Includes all other NRTI that are not in model

2

Includes all other PI that are not in the model

3

Includes ritonavir and ritonavir-boosted regimens

4

p-values from linear regression on each laboratory value (log10-transformed) adjusted for gender, race/ethnicity, Tanner stratum , BMI z-score, CDC disease category and years on each ARV drug shown in Table. Values <2nd or >98th percentile excluded